Immune Effector Cell-Associated HLH-Like Syndrome as a Post CAR T-Cell Therapy Complication of Lymphoid Malignancies
Chimeric antigen receptor T-cell (CAR-T) therapy has transformed the treatment landscape of lymphoid malignancies. However, the remarkable efficacy of CAR-T therapy is hindered by its toxicities, including an emergent one known as immune effector cell (IEC)-associated hemophagocytic lymphohistiocytosis (HLH)-like syndrome (IEC-HS), a severe and potentially life-threatening complication. This article reviews the clinical manifestations, pathophysiology, and management of IEC-HS following CAR-T therapy in B-cell malignancies.1
Clinical Features
IEC-HS is a hyperinflammatory syndrome characterized by uncontrolled activation of the immune system – particularly T cells, natural killer (NK) cells, and macrophages – which leads to a cytokine storm resulting in hemophagocytosis and multi-organ dysfunction. Following CAR-T therapy, IEC-HS can manifest clinically as fever, cytopenias, abnormal liver function tests, hyperferritinemia, increased concentrations of pro-inflammatory cytokines (including soluble interleukin-2 receptor and C-X-C motif ligand 9), hepatosplenomegaly, coagulopathy, and neurologic symptoms. While the exact incidence of IEC-HS after CAR-T therapy remains uncertain, it is considered a rare but potentially fatal complication.
In a recently published consensus, the American Society for Transplantation and Cellular Therapy (ASTCT) defined IEC-HS as a syndrome characterized by three main features: 1) signs of macrophage activation or HLH; 2) direct relationship to IEC therapy; and 3) presence of new onset or worsening of cytopenias, elevated ferritin levels, coagulopathy with low fibrinogen, and/or liver enzyme elevation (Table 1). Importantly, although HLH-like symptoms can occur in patients experiencing cytokine release syndrome (CRS), IEC-HS typically appears later, often after CRS has begun to resolve. In fact, according to the ASTCT consensus, a key factor in diagnosing IEC-HS is its chronological independence from CRS.2
Table 1. ASTCT criteria for IEC-HS
| Definition | The development of a pathological and biochemical hyperinflammatory syndrome independent from CRS and immune effector cell-associated neurotoxicity syndrome that 1) manifests with features of macrophage activation/HLH, 2) is attributable to IEC therapy, and 3) is associated with progression or new onset of cytopenias, hyperferritinemia, coagulopathy with hypofibrinogenemia, and/or transaminitis |
| Criteria for identification | Clinical or laboratory manifestations |
| Most common manifestations | Elevated and/or rapidly rising ferritin (required) |
| Onset with resolving/resolved CRS or worsening inflammatory response after initial improvement with CRS-directed therapy | |
| Hepatic transaminase elevation | |
| Hypofibrinogenemia | |
| Hemophagocytosis in bone marrow or other tissues | |
| Cytopenias | |
| Other manifestations that may be present | Lactate dehydrogenase elevations |
| Other coagulation abnormalities | |
| Direct hyperbilirubinemia | |
| New-onset splenomegaly | |
| Fever | |
| Neurotoxicity | |
| Pulmonary manifestations | |
| Renal insufficiency | |
| Hypertriglyceridemia |
Pathophysiology
The pathogenesis of HLH post CAR-T therapy is multifactorial and may involve immune dysregulation, excessive cytokine release, and macrophage activation syndrome. CAR T cells, when activated by tumor antigens, can trigger a strong immune response, releasing cytokines like interleukin 6, tumor necrosis factor alpha, and interferon gamma. This intense cytokine surge hyperactivates T cells, macrophages, and NK cells, leading to dysregulated macrophage activation and hemophagocytosis, causing HLH.3
Management Strategies
Early recognition and prompt treatment are critical for managing IEC-HS. Although secondary HLH treatment varies due to its diverse causes, high-dose corticosteroids are often utilized. Targeted therapies like anakinra, ruxolitinib, and tocilizumab may also help control inflammation in IEC-HS. Recently, the FDA-approved emapalumab, effective in primary HLH, has gained off-label use in IEC-HS for its biologic impact and safety. Supportive care, such as fluids, antibiotics, transfusions, and organ-specific interventions, are essential.4
Clinical Considerations and Future Directions
Several clinical considerations merit attention in the management of IEC-HS. These include the implementation of ASTCT consensus guidelines for diagnosis and management, development of risk stratification algorithms to identify patients at high risk of IEC-HS, and novel therapeutic strategies targeting specific immune pathways implicated in IEC-HS pathogenesis. Furthermore, long-term monitoring and surveillance are crucial to detect late-onset complications and optimize patient outcomes.5
Conclusion
IEC-HS represents a rare but potentially life-threatening complication of post-CAR-T therapy in B-cell malignancies, necessitating vigilant monitoring and timely intervention. Early recognition and a multidisciplinary approach are key to improving outcomes.
- Teachey DT, Bishop MR, Maloney DG, et al. Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'. Nat Rev Clin Oncol. 2018;15(4):218.
- Hines MR, Knight TE, McNerney KO, et al. Immune effector cell associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS). Transplant Cell Ther. 2023;29(7):438.e1-438.e16.
- Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625-638.
- Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T-cell therapy – assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15(1):47-62.
- Schuster SJ, Svoboda J, Chong EA, et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med. 2017;377(26):2545-2554.
Drs. Ombada and Sandhu indicated no relevant conflicts of interest.
Acknowledgment: This article was edited by Drs. Natalia Tijaro Ovalle and Urshila Durani
Help ASH Build an Inclusive Hematology Community!
ASH is committed to building and nurturing a global hematology community and workforce inclusive of diverse perspectives, talents, and experiences as it works toward one collective goal: helping hematologists conquer blood diseases worldwide.
How Can You Help?
Visit your My Account page, make needed updates to your demographic details, and select your preferred level of ASH access to your information; aggregated or individually identifiable, or choose not to provide or share your information. By sharing information about who you are, you will help ASH have a better appreciation of the diverse needs and talents present in the field, and help to build a more inclusive, collaborative hematology community. It will take only a few moments to complete!
Update Access to Demographic Information Learn About Our Mission